Migraine in children and adolescents are a significant cause of disability, though evidence on preventive treatments in this population remains limited. To address this gap, a study evaluated the efficacy of fremanezumab, a monoclonal antibody targeting calcitonin gene-related peptide, in 237 participants with episodic migraine aged 6 to 17 years. The study found that fremanezumab reduced monthly migraine days from baseline by 2.5 days compared with 1.4 days with placebo and reduced days with at least moderate headache severity by 2.6 days compared with 1.5 days with placebo.
A ≥50% reduction in monthly migraine days was observed in 47.2% of participants receiving fremanezumab compared with 27.0% with placebo. Injection-site erythema was the most common adverse event, occurring in 9.8% of the fremanezumab group versus 5.4% in the placebo group. These findings suggest that fremanezumab…
